Expert Review of Anticancer Therapy最新文献_第5页

Progress in histology specific treatments in soft tissue sarcoma. 软组织肉瘤组织学特异性治疗的进展。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-09-01 Epub Date: 2024-08-05 DOI: 10.1080/14737140.2024.2384584

Stefano Radaelli, Alessandra Merlini, Misbah Khan, Alessandro Gronchi

{"title":"Progress in histology specific treatments in soft tissue sarcoma.","authors":"Stefano Radaelli, Alessandra Merlini, Misbah Khan, Alessandro Gronchi","doi":"10.1080/14737140.2024.2384584","DOIUrl":"10.1080/14737140.2024.2384584","url":null,"abstract":"Introduction: Soft tissue sarcomas (STS) represent a heterogenous group of rare tumors, primarily treated with surgery. Preoperative radiotherapy is often recommended for extremity high-risk STS. Neoadjuvant chemotherapy, typically based on doxorubicin with ifosfamide, has shown efficacy in limbs and trunk wall STS. Second-line chemotherapy, commonly utilized in the metastatic setting, is mostly histology-driven. Molecular targeted agents are used across various histologies, and although the use of immunotherapy in STS is still in its early stages, there is increasing interest in exploring its potential.Areas covered: This article involved an extensive recent search on PubMed. It explored the current treatment landscape for localized and metastatic STS, focusing on the combined use of radiotherapy and chemotherapy for both extremity and retroperitoneal tumors, and with a particular emphasis on the most innovative histopathology driven therapeutic approaches. Additionally, ongoing clinical trials identified via clinicaltrials.gov are included.Expert opinion: Recently there have been advancements in the treatment of STS, largely driven by the outcomes of clinical trials. However further research is imperative to comprehend the effect of chemotherapy, targeted therapy and immunotherapy in various STS, as well as to identify biomarkers able to predict which patients are most likely to benefit from these treatments.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"845-868"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC. ABBV-184是一种同类首创的T细胞受体/抗CD3双特异性蛋白，在曾接受过治疗的AML或NSCLC成人患者中的首次人体临床试验结果。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1080/14737140.2024.2373888

Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, Abraham Avigdor, Toshio Shimizu

{"title":"First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.","authors":"Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, Abraham Avigdor, Toshio Shimizu","doi":"10.1080/14737140.2024.2373888","DOIUrl":"10.1080/14737140.2024.2373888","url":null,"abstract":"Background: ABBV-184, a novel survivin peptide-targeting T-cell receptor (TCR)/anti-CD3 bispecific protein, demonstrated preclinical T-cell activation and cytotoxicity toward HLA-A2:01-positive tumor lines. This first-in-human trial evaluated ABBV-184 monotherapy in patients with acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).Research design and methods: This phase 1 multicenter, open-label, dose escalation trial (NCT04272203) enrolled adult patients with relapsed/refractory AML or NSCLC with an HLA-A2:01 restricted genotype. Patients received ABBV-184 at 0.07 ug/kg initially, with 2- to 3-fold dose increases. The primary objective was determining the ABBV-184 recommended phase 2 dose. Secondary objectives included safety, tolerability, pharmacokinetics, and immunogenicity assessments.Results: Fifteen patients enrolled in the dose escalation (8 AML and 7 NSCLC). ABBV-184 doses ranged from 0.07 mg/kg-0.7 µg/kg, with a half-life of approximately 13-29 hours. Transient cytokine increases were observed at all dose levels, and in patients with NSCLC, transient peripheral blood lymphocyte decreases were observed. The most frequently reported treatment-emergent adverse events (TEAEs) were anemia, diarrhea, and headache. Grade 1-2 infusion-related reaction (IRR) and cytokine release syndrome (CRS) TEAEs were reported.Conclusions: ABBV-184 was well tolerated and demonstrated preliminary evidence of CD3 engagement with transient cytokine increases and peripheral lymphocyte decreases.Clinical trial registration: NCT04272203.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"893-904"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer. MMR-d/MSI-H 复发/转移性子宫内膜癌的免疫疗法。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-14 DOI: 10.1080/14737140.2024.2367472

Renata Pacholczak-Madej, Michele Bartoletti, Lucia Musacchio, Mirosława Püsküllüoglu, Paweł Blecharz, Domenica Lorusso

{"title":"Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.","authors":"Renata Pacholczak-Madej, Michele Bartoletti, Lucia Musacchio, Mirosława Püsküllüoglu, Paweł Blecharz, Domenica Lorusso","doi":"10.1080/14737140.2024.2367472","DOIUrl":"10.1080/14737140.2024.2367472","url":null,"abstract":"Introduction: The advent of immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the management of mismatch repair deficient (MMR-d)/microsatellite instability-high (MSI-H) endometrial cancer (EC). Initially investigated as monotherapy in phase I-II clinical trials for recurrent disease, immunotherapy demonstrated remarkable activity, yielding overall response rates (ORR) ranging from 27% to 58%. Based on these promising findings, phase III trials have explored the integration of immunotherapy into first-line treatment regimens for advanced/recurrent EC in combination with chemotherapy or other agents such as tyrosine kinase inhibitors (TKIs), resulting in improved ORR, progression-free survival, and overall survival compared to the standard chemotherapy regimen of paclitaxel and carboplatin. As a result, the incorporation of ICIs with standard platinum-based chemotherapy is becoming a new standard of care in MMR-d/MSI-H EC.Areas covered: This review synthesizes literature from PubMed, Embase databases, and recent congress abstracts on gynecological cancers. It covers MMR-d/MSI-H EC incidence, molecular diagnostics, clinical trial outcomes, predictive biomarkers for ICIs, patient profiles likely to benefit, resistance mechanisms, and the future of immunotherapy in this setting.Expert opinion: By offering a comprehensive overview, this review delineates the pivotal role of ICIs in the management of MMR-d/MSI-H EC.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"717-729"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Augmenting the landscape of chimeric antigen receptor T-cell therapy. 增强嵌合抗原受体 T 细胞疗法的前景。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1080/14737140.2024.2372330

Shalini Srivastava, Sanjay Singh, Ajay Singh

{"title":"Augmenting the landscape of chimeric antigen receptor T-cell therapy.","authors":"Shalini Srivastava, Sanjay Singh, Ajay Singh","doi":"10.1080/14737140.2024.2372330","DOIUrl":"10.1080/14737140.2024.2372330","url":null,"abstract":"Introduction: The inception of recombinant DNA technology and live cell genomic alteration have paved the path for the excellence of cell and gene therapies and often provided the first curative treatment for many indications. The approval of the first Chimeric Antigen Receptor (CAR) T-cell therapy was one of the breakthrough innovations that became the headline in 2017. Currently, the therapy is primarily restricted to a few nations, and the market is growing at a CAGR (current annual growth rate) of 11.6% (2022-2032), as opposed to the established bio-therapeutic market at a CAGR of 15.9% (2023-2030). The limited technology democratization is attributed to its autologous nature, lack of awareness, therapy inclusion criteria, high infrastructure cost, trained personnel, complex manufacturing processes, regulatory challenges, recurrence of the disease, and long-term follow-ups.Areas covered: This review discusses the vision and strategies focusing on the CAR T-cell therapy democratization with mitigation plans. Further, it also covers the strategies to leverage the mRNA-based CAR T platform for building an ecosystem to ensure availability, accessibility, and affordability to the community.Expert opinion: mRNA-guided CAR T cell therapy is a rapidly growing area wherein a collaborative approach among the stakeholders is needed for its success.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"755-773"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives. 复发性卵巢癌的 Relacorilant：临床证据与未来展望。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-11 DOI: 10.1080/14737140.2024.2362178

Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy, Anna Fagotti, Giovanni Scambia, Claudia Marchetti

{"title":"Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives.","authors":"Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy, Anna Fagotti, Giovanni Scambia, Claudia Marchetti","doi":"10.1080/14737140.2024.2362178","DOIUrl":"10.1080/14737140.2024.2362178","url":null,"abstract":"Introduction: Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting.Areas covered: Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy.Expert opinion: Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"649-655"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. 2024 年 ASCO 泌尿生殖系统癌症研讨会：聚焦肾细胞癌。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI: 10.1080/14737140.2024.2370382

Viria Beccia, Daniela Arduini, Roberto Iacovelli, Alessandro Scala, Denis Occhipinti, Chiara Ligato, Luigi Roca, Pierluigi Russo, Nazario Foschi, Giampaolo Tortora, Chiara Ciccarese

{"title":"2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma.","authors":"Viria Beccia, Daniela Arduini, Roberto Iacovelli, Alessandro Scala, Denis Occhipinti, Chiara Ligato, Luigi Roca, Pierluigi Russo, Nazario Foschi, Giampaolo Tortora, Chiara Ciccarese","doi":"10.1080/14737140.2024.2370382","DOIUrl":"10.1080/14737140.2024.2370382","url":null,"abstract":"In this article, we report the breakthrough acquisitions for renal cell carcinoma (RCC) management presented at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. The results from Keynote 564 showed an impressive overall survival (OS) advantage for pembrolizumab, in patients at higher risk of relapse after surgery and confirmed the benefit in terms of disease-free survival (DFS). Until now, pembrolizumab is the only immune checkpoint inhibitor (ICI) to prove a survival advantage. On the contrary, the results from CheckMate 914 trial showed the lack of benefit of adjuvant nivolumab. In the metastatic setting, the longer-term follow-up data of the CheckMate 9ER and CheckMate 214 trials reassessed the undoubtable role of ICI-based combination in first-line treatment, with a clear survival advantage in the subgroup of patients at intermediate/poor IMDC prognosis. No OS advantage was seen in favorable IMDC risk group patients. This 2024 ASCO Genitourinary Cancer Symposium laid the foundations for further knowledge development necessary for an increasingly personalized therapy for RCC patients.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"657-660"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer. 2024 年 ASCO 泌尿生殖系统专题讨论会要点：聚焦尿路上皮癌和前列腺癌。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-06-27 DOI: 10.1080/14737140.2024.2370384

Alessandro Strusi, Giada Pinterpe, Chiara Ciccarese, Romina Rose Pedone, Michele Sarcina, Valeria Sardaro, Rachele Belletto, Angelo Totaro, Marco Racioppi, Rossana Berardi, Giampaolo Tortora, Roberto Iacovelli

引用次数: 0

Risks and benefits of sentinel lymph node evaluation in the management of endometrial intraepithelial neoplasia. 前哨淋巴结评估在子宫内膜上皮内瘤治疗中的风险和益处。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-18 DOI: 10.1080/14737140.2024.2372329

Lauren M Lim, Hadi Erfani, Katelyn B Furey, Koji Matsuo, X Mona Guo

{"title":"Risks and benefits of sentinel lymph node evaluation in the management of endometrial intraepithelial neoplasia.","authors":"Lauren M Lim, Hadi Erfani, Katelyn B Furey, Koji Matsuo, X Mona Guo","doi":"10.1080/14737140.2024.2372329","DOIUrl":"10.1080/14737140.2024.2372329","url":null,"abstract":"Introduction: Endometroid intraepithelial neoplasia (EIN) is a premalignant lesion to endometrial cancer. Increasing number of gynecologic oncologists are performing sentinel lymph node (SLN) evaluation during hysterectomy for EIN to ensure complete staging if there is cancer on the final specimen. However, there are no clear guidelines and the benefits and risks to performing SLN evaluation for EIN patients are unclear.Areas covered: This narrative review examines the advantages and disadvantages of SLN evaluation for EIN patients and provides an algorithm to assist clinicians in selectively applying the procedure for maximal patient benefit. Relevant articles up to March 2024 were obtained from a PubMed search on SLN use with endometrial pathology.Expert opinion: Sentinel lymph node evaluation for patients with EIN is safe, feasible, and particularly important for the approximately 10% of patients with high-risk endometrial carcinoma on final pathology. However, as most diagnosed carcinomas are low-risk, SLN evaluation would have limited oncologic benefit. While SLN assessment may overtreat most patients with EIN, a significant minority of patients will be improperly staged. We propose an algorithm highlighting the importance of maximal preoperative endometrial sampling and stratifying patients via risk factors to selectively identify those who would benefit most from SLN evaluation.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"745-753"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals. 用于癌症治疗的多靶点多聚芳香醚疗法。理论概念和建议。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-08 DOI: 10.1080/14737140.2024.2372336

Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui

{"title":"Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals.","authors":"Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui","doi":"10.1080/14737140.2024.2372336","DOIUrl":"10.1080/14737140.2024.2372336","url":null,"abstract":"Introduction: The pharmacological treatment of cancer has evolved from cytotoxic to molecular targeted therapy. The median survival gains of 124 drugs approved by the FDA from 2003 to 2021 is 2.8 months. Targeted therapy is based on the somatic mutation theory, which has some paradoxes and limitations. While efforts of targeted therapy must continue, we must study newer approaches that could advance therapy and affordability for patients.Areas covered: This work briefly overviews how cancer therapy has evolved from cytotoxic chemotherapy to current molecular-targeted therapy. The limitations of the one-target, one-drug approach considering cancer as a robust system and the basis for multitargeting approach with polypharmacotherapy using repurposing drugs.Expert opinion: Multitargeted polypharmacotherapy for cancer with repurposed drugs should be systematically investigated in preclinical and clinical studies. Remarkably, most of these proposed drugs already have a long history in the clinical setting, and their safety is known. In principle, the risk of their simultaneous administration should not be greater than that of a first-in-human phase I study as long as the protocol is developed with strict vigilance to detect early possible side effects from their potential interactions. Research on cancer therapy should go beyond the prevailing paradigm targeted therapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"665-677"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 在监测早期和晚期乳腺癌方面，ctDNA 是否已准备好超越成像技术？

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-08-01 Epub Date: 2024-07-01 DOI: 10.1080/14737140.2024.2362173

Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, Elisabetta Molteni, Linda Cucciniello, Lucia Da Ros, Buriolla Silvia, Lorenzo Cereser, Rossana Roncato, Lorenzo Gerratana, Fabio Puglisi

{"title":"Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?","authors":"Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, Elisabetta Molteni, Linda Cucciniello, Lucia Da Ros, Buriolla Silvia, Lorenzo Cereser, Rossana Roncato, Lorenzo Gerratana, Fabio Puglisi","doi":"10.1080/14737140.2024.2362173","DOIUrl":"10.1080/14737140.2024.2362173","url":null,"abstract":"Introduction: Circulating tumor DNA (ctDNA) and radiological imaging are increasingly recognized as crucial elements in breast cancer management. While radiology remains the cornerstone for screening and monitoring, ctDNA holds distinctive advantages in anticipating diagnosis, recurrence, or progression, providing concurrent biological insights complementary to imaging results.Areas covered: This review delves into the current evidence on the synergistic relationship between ctDNA and imaging in breast cancer. It presents data on the clinical validity and utility of ctDNA in both early and advanced settings, providing insights into emerging liquid biopsy techniques like epigenetics and fragmentomics. Simultaneously, it explores the present and future landscape of imaging methodologies, particularly focusing on radiomics.Expert opinion: Numerous are the current technical, strategic, and economic challenges preventing the clinical integration of ctDNA analysis in the breast cancer monitoring. Understanding these complexities and devising targeted strategies is pivotal to effectively embedding this methodology into personalized patient care.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"679-691"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0